NCT07086118 Dexamethasone Versus Metoclopramide for Prophylaxis of Nausea and Vomiting After Cataract Surgery
| NCT ID | NCT07086118 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Alexandria University |
| Condition | Cataract |
| Study Type | INTERVENTIONAL |
| Enrollment | 210 participants |
| Start Date | 2025-05-01 |
| Primary Completion | 2025-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 210 participants in total. It began in 2025-05-01 with a primary completion date of 2025-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Postoperative nausea and vomiting (PONV) is a common consequence of ambulatory surgery, affecting up to 80% of high-risk patients and 20-30% overall. Despite being widespread, a prior survey found that patients are more averse to PONV than pain and other significant postoperative problems. Furthermore, even mild cases of PONV can have serious repercussions, such as postanesthesia care unit (PACU) workflow disruption, delayed discharges, higher medical costs, and lower patient satisfaction.PONV following intraocular surgery can be unpleasant and may lead to serious complications including suprachoroidal hemorrhage (SCH). SCH is a potentially serious condition that occurs when the posterior ciliary arteries or vortex veins burst, resulting in blood in the suprachoroidal region. The hypothesis is that dexamethasone will lower the incidence of PONV after cataract surgery when compared with metoclopramide.
Eligibility Criteria
Inclusion Criteria: * Age: 40-80 years, both sexes. * ASA physical status class I to III. Exclusion Criteria: * history of motion sickness * patients with gastrointestinal disorders or gastro-oesophageal reflux * patients taking medications with known antiemetic activity * previous postoperative vomiting * allergy to bupivacaine * allergy to metoclopramide or dexamethasone
Contact & Investigator
sarah m elgamal, MD
PRINCIPAL INVESTIGATOR
Alexandria University
Frequently Asked Questions
Who can join the NCT07086118 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 80 Years, studying Cataract. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07086118 currently recruiting?
Yes, NCT07086118 is actively recruiting participants. Contact the research team at sarahelgamal1990@yahoo.com for enrollment information.
Where is the NCT07086118 trial being conducted?
This trial is being conducted at Alexandria, Egypt.
Who is sponsoring the NCT07086118 clinical trial?
NCT07086118 is sponsored by Alexandria University. The principal investigator is sarah m elgamal, MD at Alexandria University. The trial plans to enroll 210 participants.